Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Accured Expenses (2022 - 2025)

Amylyx Pharmaceuticals has reported Change in Accured Expenses over the past 4 years, most recently at -$1.2 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at -$1.2 million for Q4 2025, up 95.42% from a year ago — trailing twelve months through Dec 2025 was -$6.6 million (up 88.97% YoY), and the annual figure for FY2025 was -$6.6 million, up 88.97%.
  • Change in Accured Expenses for Q4 2025 was -$1.2 million at Amylyx Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for AMLX hit a ceiling of $20.8 million in Q4 2023 and a floor of -$26.4 million in Q4 2024.
  • Median Change in Accured Expenses over the past 4 years was -$146000.0 (2023), compared with a mean of -$2.3 million.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 8879.45% in 2024 and later soared 143.08% in 2025.
  • Amylyx Pharmaceuticals' Change in Accured Expenses stood at $5.7 million in 2022, then soared by 267.58% to $20.8 million in 2023, then tumbled by 227.07% to -$26.4 million in 2024, then surged by 95.42% to -$1.2 million in 2025.
  • The last three reported values for Change in Accured Expenses were -$1.2 million (Q4 2025), $1.1 million (Q3 2025), and $5.4 million (Q2 2025) per Business Quant data.